Aeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, Feb. 7, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that Paul Blake, MD,\n the Company's Senior Vice President and Chief of Medical Affairs, will\n be presenting a Company overview at the BIO CEO Investor Conference on\n Tuesday, February 14, 2012, at 3:30 pm (Eastern), in the Duke of\n Windsor Room of the Waldorf Astoria Hotel in New York City.\n\n\nDr. Blake will also take part in a cancer panel during the RBC Capital\n Markets Global Healthcare Conference on Tuesday, February 28, 2012 at\n 11:00 am (Eastern) in the Holmes Room 1 of the New York Palace Hotel in\n New York City.\n\n\nLive audio webcasts of these presentations will be available on Aeterna\n Zentaris' website at www.aezsinc.com, in the Newsroom section. A replay of the webcasts will also be\n available on the Company's website for a period of 90 days.\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a late-stage oncology drug development company\n currently investigating potential treatments for various cancers\n including colorectal, multiple myeloma, endometrial, ovarian, prostate\n and bladder cancer. The Company's innovative approach of \"personalized\n medicine\" means tailoring treatments to a patient's specific condition\n and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn\n from its proprietary discovery unit providing the Company with constant\n and long-term access to state-of-the-art therapeutic options. For more\n information please visit www.aezsinc.com.\n\n Investor Relations Ginette Beaudet Vallières Investor Relations Coordinator (418) 652-8525 ext. [email protected] Chad Rubin Vice President The Trout Group LLC (646) [email protected] Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. [email protected] \n","length":2167,"tagName":"div"}]

More updates from Cosciens Biopharma Inc.